The stock of Neos Therapeutics Inc (NASDAQ:NEOS) hit a new 52-week low and has $5.00 target or 13.00% below today’s $5.75 share price. The 8 months bearish chart indicates high risk for the $92.41 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $5.00 price target is reached, the company will be worth $12.01M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 2.54% or $0.15 during the last trading session, hitting $5.75. About 70,308 shares traded hands. Neos Therapeutics Inc (NASDAQ:NEOS) has declined 45.32% since March 31, 2016 and is downtrending. It has underperformed by 47.84% the S&P500.
Analysts await Neos Therapeutics Inc (NASDAQ:NEOS) to report earnings on November, 8. They expect $-1.61 EPS, down 159.68% or $0.99 from last year’s $-0.62 per share. After $-1.58 actual EPS reported by Neos Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.90% negative EPS growth.
Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage
Out of 4 analysts covering Neos Therapeutics (NASDAQ:NEOS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neos Therapeutics has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. JMP Securities initiated Neos Therapeutics Inc (NASDAQ:NEOS) on Monday, August 17 with “Market Outperform” rating. BMO Capital Markets initiated the shares of NEOS in a report on Monday, August 17 with “Outperform” rating. The company was maintained on Thursday, November 12 by RBC Capital Markets. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. On Wednesday, June 29 the stock rating was initiated by BMO Capital Markets with “Outperform”. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Outperform” rating given on Monday, August 17 by RBC Capital Markets. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Outperform” rating given on Friday, February 19 by Wells Fargo.
According to Zacks Investment Research, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.”
More notable recent Neos Therapeutics Inc (NASDAQ:NEOS) news were published by: Businesswire.com which released: “Robbins Arroyo LLP Is Investigating the Officers and Directors of Neos …” on November 01, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on September 19, 2016, Quotes.Wsj.com published: “News Neos Therapeutics Inc.NEOS” on April 22, 2015. More interesting news about Neos Therapeutics Inc (NASDAQ:NEOS) were released by: Globenewswire.com and their article: “Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla …” published on November 10, 2015 as well as Globenewswire.com‘s news article titled: “Neos Therapeutics Announces Pricing of Initial Public Offering” with publication date: July 23, 2015.
NEOS Company Profile
Neos Therapeutics, Inc., incorporated on June 15, 2009, is a pharmaceutical company. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. The Firm has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). The Company’s product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. The Company’s branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. The Company’s modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.